Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18907087 | BINDING AGENTS AND METHODS OF USING THE SAME | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18734892 | TAU BINDING COMPOUNDS | June 2024 | February 2025 | Allow | 8 | 1 | 0 | No | No |
| 18183840 | BISPECIFIC GPC3xCD28 AND GPC3xCD3 ANTIBODIES AND THEIR COMBINATION FOR TARGETED KILLING OF GPC3 POSITIVE MALIGNANT CELLS | March 2023 | June 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18099448 | ANTI-CANINE CD16 POLYPEPTIDES, ANTI-CANINE CD64 POLYPEPTIDES, COMPOSITIONS INCLUDING SAME, AND METHODS OF USING | January 2023 | November 2024 | Allow | 22 | 2 | 1 | Yes | No |
| 18056679 | DICKKOPF-1 VARIANT ANTIBODIES AND METHODS OF USE | November 2022 | July 2024 | Allow | 19 | 1 | 1 | No | No |
| 17964213 | BRAIN-TARGETING SINGLE DOMAIN ANTIBODIES AND PURIFICATION METHODS | October 2022 | July 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 18045671 | METHODS OF EFFECTING A HEMODYNAMIC CHANGE BY ADMINISTERING AN ANTI-NPR1 ANTIBODY | October 2022 | November 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17596066 | USE OF PRG4 TO TREAT CANCER | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17615508 | ALK7 BINDING PROTEINS AND USES THEREOF | November 2021 | March 2025 | Allow | 40 | 1 | 0 | No | No |
| 17605933 | MONOCLONAL ANTIBODY THAT BINDS SPECIFICALLY TO GITR | October 2021 | June 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17600862 | THERAPEUTIC ANTIBODIES FOR TREATING LUNG CANCER | October 2021 | March 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17437771 | ANTI-VBETA17/ANTI-CD123 BISPECIFIC ANTIBODIES | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17431218 | BISPECIFIC ANTIBODY SPECIFICALLY BINDING TO GPNMB AND CD3, AND USE THEREOF | August 2021 | February 2025 | Allow | 42 | 1 | 1 | No | No |
| 17391821 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | August 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17443888 | VARIABLE REGION SEQUENCE OF BROAD-SPECTRUM ANTIBODY AGAINST CLOTHIANIDIN AND DINOTEFURAN AND PREPARATION OF INTACT RECOMBINANT ANTIBODY THEREOF | July 2021 | September 2024 | Allow | 37 | 1 | 0 | No | No |
| 17425296 | ANTI-PD-L1 DIABODIES AND THE USE THEREOF | July 2021 | January 2025 | Allow | 41 | 1 | 0 | No | No |
| 17375940 | ANTIBODIES BINDING CTLA-4 AND USES THEREOF | July 2021 | September 2024 | Allow | 38 | 0 | 0 | No | No |
| 17418447 | BISPECIFIC ANTIBODY BINDING TO TfR | June 2021 | November 2024 | Allow | 41 | 0 | 1 | No | No |
| 17417239 | ACTIVATABLE MASKED ANTI-CTLA4 BINDING PROTEINS | June 2021 | April 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17309713 | REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIA ANTIBODIES AND USES THEREOF | June 2021 | January 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17413496 | ANTI-HUMAN CSF-1R ANTIBODY AND USES THEREOF | June 2021 | May 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17311085 | MODIFIED PRODUCT OF FC DOMAIN OF ANTIBODY | June 2021 | March 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17297719 | ANTI-PD-L1 ANTIBODY PREPARATION | May 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17293729 | FUSION PROTEIN AND USE THEREOF | May 2021 | March 2025 | Allow | 46 | 1 | 1 | No | No |
| 17292739 | A MULTISPECIFIC ANTIBODY AND PREPARATION METHOD AND USE THEREOF | May 2021 | May 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17292592 | SINGLE DOMAIN ANTIBODIES THAT BIND HUMAN SERUM ALBUMIN | May 2021 | January 2025 | Allow | 44 | 1 | 0 | No | No |
| 17292488 | ANTI-B7-H3 ANTIBODY, PREPARATION METHOD THEREFOR, CONJUGATE AND APPLICATION THEREOF | May 2021 | January 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17290352 | NOVEL ANTAGONISTIC ANTI-TNFR2 ANTIBODIES | April 2021 | May 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17286011 | Compositions and Methods for Treatment of Liver Disease | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17285952 | RGMC-SELECTIVE INHIBITORS AND USE THEREOF | April 2021 | January 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17283842 | HUMANIZED MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-6, ENCODING GENES AND USES THEREOF | April 2021 | February 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17276779 | EGFR BINDING PROTEINS AND METHODS OF USE | March 2021 | September 2024 | Allow | 42 | 1 | 1 | No | No |
| 17191710 | DEVELOPMENT OF RECOMBINANT CHICKEN IGY MONOCLONAL ANTIBODY AND SCFV ANTIBODIES RAISED AGAINST HUMAN TYMIDINE KINASE 1 EXPRESSED IN MAMMALIAN CELLS AND USE THEREOF | March 2021 | September 2024 | Allow | 43 | 2 | 0 | No | No |
| 17272136 | COMPOSITIONS AND METHODS FOR ENHANCING DONOR OLIGONUCLEOTIDE-BASED GENE EDITING | February 2021 | June 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17264388 | ANTIGEN-BINDING MOLECULE CONTAINING TWO ANTIGEN-BINDING DOMAINS THAT ARE LINKED TO EACH OTHER | January 2021 | June 2025 | Allow | 53 | 3 | 0 | No | No |
| 17261823 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING TARGET SPECIFIC FUSION PROTEINS | January 2021 | July 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17144588 | ANTIBODIES SPECIFIC TO FOLATE RECEPTOR ALPHA | January 2021 | March 2025 | Allow | 51 | 1 | 1 | Yes | No |
| 17143386 | ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | January 2021 | December 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 17132324 | MONOCLONAL ANTIBODIES ACTIVATING CD40 AND USES THEREOF | December 2020 | January 2024 | Allow | 36 | 0 | 0 | No | No |
| 17252069 | SCREENING METHODS USING GPRC6A TASTE RECEPTORS AND PET FOOD PRODUCTS AND COMPOSITIONS PREPARED USING THE SAME | December 2020 | July 2024 | Allow | 44 | 2 | 1 | Yes | No |
| 17046601 | De-immunized Factor VIII Molecule and Pharmaceutical Compositions Comprising the Same | October 2020 | August 2024 | Allow | 47 | 2 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner SHUPE, ELIZABETH A works in Art Unit 1643 and has examined 39 patent applications in our dataset. With an allowance rate of 79.5%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner SHUPE, ELIZABETH A's allowance rate of 79.5% places them in the 41% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by SHUPE, ELIZABETH A receive 1.21 office actions before reaching final disposition. This places the examiner in the 20% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SHUPE, ELIZABETH A is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.4% benefit to allowance rate for applications examined by SHUPE, ELIZABETH A. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 90.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 12.9% of allowed cases (in the 90% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.